All In Biotech

Drug Trial Radar · NCT06841315

A Varegacestat Hepatic Impairment Study

A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Varegacestat in Participants With or Without Hepatic Impairment

Last checked: Nov 20, 2026Latest source record: Mar 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

35

Actual

Start

Mar 7, 2025

Primary completion

Nov 5, 2025

Study completion Mar 6, 2026

Sponsor

Lead sponsor
Immunome, Inc.Industry
Sponsor type
Industry
First posted
Feb 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 84 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This clinical trial is designed to determine the pharmacokinetics, safety and tolerability of varegacestat in people with impaired liver function compared to people with normal liver function.

Conditions

  • Healthy Volunteer
  • Hepatic Impairment (HI)

Interventions

  • varegacestatDrug

    experimental intervention

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PK of varegacestat and metabolite from a single oral dose of varegacestat in hepatic impaired adult participants to matched healthy adult participants.Time frame: Up to 4 weeks
  2. PK of varegacestat and metabolite from a single oral dose of varegacestat in hepatic impaired adult participants to matched healthy adult participants.Time frame: Up to 4 weeks
  3. PK of varegacestat and metabolite from a single oral dose of varegacestat in hepatic impaired adult participants to matched healthy adult participants.Time frame: Up to 4 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Orlando Clinical Research Center

    Orlando, Florida

  • The Texas Liver Institute

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.